Mark A. Henderson, MD



Affiliate Associate Professor


Radiation Medicine


BA in Chemistry and BS in Biology from the University of Evansville in Evansville, IN

Medical Education:

MD from Indiana University School of Medicine in Indianapolis, IN

Residency Training:

Internship in Internal Medicine at Indiana University School of Medicine
Residency in Radiation Oncology at Indiana University School of Medicine

Interest and Accomplishments:

In 2015, Dr. Henderson was elected the Secretary/Treasurer of the Southwest Oregon Medical Society (SWOMS). He is serving as the Vice President of SWOMS for 2016, will serve as the President in 2017, and will serve as the Past President in 2018.

Since 2015, Dr. Henderson has been on the board of trustees for the Oregon Medical Association (OMA) as the representative for SWOMS.

In 2014, Dr. Henderson became the radiation oncology medical director for what is now the Bay Area Cancer Center at Bay Area Hospital in Coos Bay, Oregon. As medical director, he is helping the program upgrade technology and bring new radiation treatment options to the southern Oregon coast.

In 2013, Dr. Henderson was inducted into the Alpha Omega Alpha Honor Medical Society as a faculty member at Indiana University School of Medicine.

From 2010-2014, Dr. Henderson was the medical director of the Indiana University Health Methodist Hospital Department of Radiation Therapy in Indianapolis, IN. He was also an Assistant Professor of Clinical Radiation Oncology at the Indiana University School of Medicine, with research focuses on the treatment of CNS tumors and on better understanding and avoidance of toxicity from stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer.

Selected Publications:

Timur Mitin, Aditya Jain, Catherine Degnin, Yiyi Chen, Mark Henderson, Charles R. Thomas, Jr. Current patterns of care for patients with extensive stage small cell lung cancer: Survey of US radiation oncologists on their recommendations regarding thoracic consolidation radiotherapy. Lung Cancer 100: 85-89 (2016).

Aditya Jain, Jia Luo, Yiyi Chen, Mark A. Henderson, Charles R. Thomas Jr, Timur Mitin. Current patterns of care for patients with extensive-stage SCLC: Survey of US radiation oncologists on their recommendations regarding prophylactic cranial irradiation. J Thoracic Oncology 11(8): 1305-1310 (2016).

Neil C. Estabrook, Stephen, T. Lutz, Cynthia S. Johnson, Simon S. Lo, Mark A. Henderson. Does Graded Prognostic Assessment outperform Recursive Partitioning Analysis in patients with moderate prognosis brain metastases? CNS Oncology 5(2): 69-76 (2016).

Mark W. McDonald, David A. Plankenhorn, Kevin P. McMullen, Mark A. Henderson, Edward J. Dropcho, Mitesh V. Shah, Aaron A. Cohen-Gadol. Proton therapy for atypical meningiomas. J Neurooncol 123(1):123-128 (2015).

Simon Shek-Man Lo, Elizabeth M. Gore, Jeffrey D. Bradley, John M. Buatti, Isabelle Germano, A. Paiman Ghafoori, Mark A. Henderson, Gregory J.A. Murad, Roy A. Patchell, Samir H. Patel, Jared R. Robbins, H. Ian Robins, Andrew D. Vassil, Franz J. Wippold II, Michael J. Yunes, Gregory M.M. Videtic. ACR Appropriateness Criteria Pre-Irradiation Evaluation and Management of Brain Metastases. J Palliative Medicine 17(8):880-886 (2014).

Nancy U. Lin, Rachel A. Freedman, Naren Ramakrishna, Jerry Younger, Anna Maria Storniolo, Jennifer R. Bellon, Steven E. Come, Rebecca S. Gelman, Gordon J. Harris, Mark A. Henderson, Shannon M. MacDonald, Anand Mahadevan, Emily Eisenberg, Jennifer A. Ligibel, Erica L. Mayer, Beverly Moy, April F. Eichler, Eric P. Winer. A Phase I study of lapatinib with whole brain radiotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Research and Treatment 142: 405-414 (2013)

Neil C. Estabrook, Stephen T. Lutz, Cynthia S. Johnson, Mark A. Henderson. Whole brain radiotherapy for poor prognosis patients with brain metastases: predictably poor results. Journal of Supportive Oncology. 11(4):190-195 (2013)

Samir H. Patel, Jared R. Robbins, Elizabeth M. Gore, Jeffrey D. Bradley, Laurie E. Gaspar, Isabelle Germano, Paiman Ghafoori, Mark A. Henderson, Stephen T. Lutz, Michael W. McDermott, Roy A. Patchell, Ian H. Robins, Andrew D. Vassil, Franz J. Wippold II, Gregory M. Videtic. ACR Appropriateness Criteria Follow-up and Retreatment of Brain Metastases. Am J Clin Oncol 35(3):302-306 (2012)

Marvene M. Ewing, Samuel M. Carnes, Mark A. Henderson, Indra J. Das. Dosimetric comparison of metastatic spinal photon treatment techniques. Med Dosimetry 37(4):369-373 (2012)

R. Bryan Barriger, Jeffrey A. Forquer, Jeffrey G. Brabham, David L. Andolino, Ronald H. Shapiro, Mark A. Henderson, Peter A.S. Johnstone, Achilles J. Fakiris. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 82(1):457-462 (2012)

David L. Andolino, Jeffrey A. Forquer, Mark A. Henderson, Robert B. Barriger, Ronald H. Shapio, Jeffrey G. Brabham, Peter A.S. Johnstone, Higinia R. Cardenes, Achilles J. Fakiris. Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver. Int J Radiat Oncol Biol Phys 80(3):692-697 (2011)

Mark A. Henderson, David J. Hoopes, James Fletcher, Pei-Fen Lin, Constantin T. Yiannoutsos, Mark D. Williams, Achilles J. Fakiris, Ronald C. McGarry, Robert D. Timmerman. A pilot trial of serial FDG-PET in patients with medically inoperable stage I non-small cell lung cancer treated with hypofractionated stereotactic body radiotherapy (SBRT). Int J Radiat Oncol Biol Phys 76: 789-795 (2010)

Achilles J. Fakiris, Ronald C. McGarry, Constantin Yiannoutsos, Lech Papiez, Mark Williams, Mark A. Henderson, Robert Timmerman. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: 4 year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 75(3):677-682 (2009)

Mark A. Henderson, Achilles J. Fakiris, Robert D. Timmerman, Robert M. Worth, Simon S. Lo, Thomas C. Witt. Gamma Knife Stereotactic Radiosurgery for Low-Grade Astrocytomas. Stereotact Funct Neurosurg 87(3): 161-167 (2009)

Mark Henderson, Ronald McGarry, Constantin Yiannoutsos, Achilles Fakiris, David Hoopes, Mark Williams, Robert Timmerman. Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 72: 404-409 (2008)

Brent A Tinnel, Mark A. Henderson, Thomas C. Witt, Achilles J. Fakiris, Robert M. Worth, Paul M. DesRosiers, James W. Edmondson, Robert D. Timmerman, and Simon S. Lo. Endocrine Response after Gamma Knife-Based Stereotactic Radiosurgery for Secretory Pituitary Adenoma. Stereotact Funct Neurosurg 86(5): 292-296 (2008)


In April of 2016, Dr. Henderson was a moderator for a panel focusing on the treatment of skin cancers at the 98th annual meeting of the American Radium Society (ARS) in Philadelphia, PA.

Drs. Henderson, Young, and Mitin, are all on the oral platform for the ASTRO’S 56th Annual meeting: Targeting Cancer: Technology & Biology

Dr. Mark Henderson Serves as Panel Chair